A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients.
Jung-min Lee
No relevant relationships to disclose
Christina M. Annunziata
No relevant relationships to disclose
John L. Hays
No relevant relationships to disclose
Peter L. Choyke
No relevant relationships to disclose
Liang Cao
No relevant relationships to disclose
Minshu Yu
No relevant relationships to disclose
Nilofer Saba Azad
No relevant relationships to disclose
Nicole D. Houston
No relevant relationships to disclose
Lori M. Minasian
No relevant relationships to disclose
Nicolas Gordon
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Elise C. Kohn
No relevant relationships to disclose